Document text
byNicolas Hulscher, MPHA concerningnew human studyfound that girls exposed to Tylenol during pregnancy had41% smaller ovaries, 23% fewer ovarian follicles, and 13% smaller uteruses.The study,“Fetal exposure to paracetamol is associated with altered markers of ovarian development and reduced uterine volume in girls: the COPANA study,”was just published inHuman Reproduction Open. The authors describe it as the first human cohort specifically designed to study prenatal acetaminophen exposure and ovarian development.The researchers followed 302 infant girls, while their mothers reported Tylenol/acetaminophen use every 2 weeks starting early in pregnancy, including what they took and how much. The researchers also measured acetaminophen directly in maternal urine using LC-MS/MS, then used ultrasound to examine the girls’ ovaries and uterus and measured reproductive hormones. They also checked the findings in a separate cohort of 1,210 girls followed into adolescence.The doses were not extreme. In the main cohort, the median cumulative reported dose was about2 gramsin both the early- and later-exposure groups, while the median total reported dose across pregnancy among exposed women was3 grams. In other words, this was not 2 grams every day, it was the total amount reported over the relevant pregnancy period.Among girls whose mothers reported Tylenol/acetaminophen use during pregnancy:Early fetal exposure (<17 weeks): 41% smaller ovarian volumeMid-to-late fetal exposure (≥17 weeks): 23% fewer ovarian folliclesEarly fetal exposure (<17 weeks): 13% smaller uterine volumeThere also was adose-response pattern: the more acetaminophen exposure mothers reported—and the higher the drug levels measured in urine—the smaller the ovarian and uterine volumes tended to be.The signal also extended beyond infancy. In the independent cohort, prenatalacetaminophen and/or NSAID exposurewas associated with:4.11 cm³ lower uterine volume at puberty2.76 cm³ lower ovarian volume during adolescenceThat second cohort used a less precise exposure measure and grouped acetaminophen together with NSAIDs, so it is best viewed as supportive rather than identical confirmation.They adjusted for several potential confounders, including maternal BMI, PCOS, alcohol and nicotine use, IVF conception, aspirin/NSAID use, and infant acetaminophen treatment. They also specifically tested forconfounding by indicationby excluding mothers who took acetaminophen forfever, and the main associations remained. However, they didnot account for maternal vaccination status, which leaves open the possibility that vaccination-related factors could have contributed to some of the observed associations.These findings are concerning given that more than 50% of pregnant women use acetaminophen and the drug crosses the placenta. The paper also notes that animal studies have found reductions in ovarian follicle reserve of up to 40% after fetal exposure.This was an observational study, so it cannot prove that Tylenol caused the changes. But41% smaller ovaries, 23% fewer follicles, measurable dose-response trends, and similar changes later in lifemake this a reproductive-safety signal that deserves serious attention.Nicolas Hulscher, MPHEpidemiologist and Foundation Administrator, McCullough FoundationSupport our mission:mcculloughfnd.orgPlease consider following both theMcCullough Foundationandmy personal accountonX(formerly Twitter) for further content.FOCAL POINTS (Courageous Discourse™) is a reader-supported publication. To receive new posts and support my work, consider becoming a paid subscriber.